Sequential immunophenotypic analysis of mast cells in a case of systemic mast cell disease evolving to a mast cell leukemia.
The immunophenotypic characteristics of both bone marrow (BM) and peripheral blood (PB) mast cells (MC), from a patient suffering from an aggressive systemic mast cell disease (SMCD), were sequentially analyzed by flow cytometry using direct immunofluorescence. Analysis was carried out at diagnosis, during clinical response induced by interferon alfa-2h/prednisone therapy, and later at relapse. Our results show that together with the CD117 and IgE characteristic markers, at diagnosis BM MC showed strong expression of CD11c, CD13, CD29, CD33, CD44, CD45, CD63, and CD71, and they were also positive for CD2, CD22, CD25, and CD54 although at a lower level. PB MC displayed similar immunophenotypic characteristics although they had a lower expression of CD11c, CD25, CD33, CD63, CD69, and CD71 with a higher reactivity for CD117. Unlike BM MC, PB MC were weakly positive for CD41a and CD61. Sequential studies showed decreased numbers of both BM and PB MC during clinical response associated with a higher expression of the CD29 and CD54 adhesion molecules. In turn, clinical relapse was related to increased numbers of PB and BM MC together with lower CD2, CD11c, CD45, and and CD54 expression and a higher reactivity for the CD117 and CD25 antigens. CD2 had become negative at the last follow-up study. In addition, an increased proportion of S-phase MC was observed at relapse. These findings suggest that the assessment of the quantitative expression of cell-adhesion molecules and growth-factor receptors together with cell cycle studies of mast cells could be of value for monitoring therapy and predicting clinical outcome in aggressive SMCD.
Escribano
L
L
Servicio de Hematología, Hospital Ramón y Cajal, Universidad de Alcalá de Henares, Madrid, Spain.
Orfao
A
A
Villarrubia
J
J
Martín
F
F
Madruga
J I
JI
Cuevas
M
M
Velasco
J L
JL
Rios
A
A
San Miguel
J F
JF
D000368:Aged; D000911:Antibodies, Monoclonal; D000954:Antigens, Surface / Q000032:analysis; D004273:DNA, Neoplasm / Q000032:analysis; D005260:Female; D005434:Flow Cytometry; D019085:Fluorescent Antibody Technique, Direct; D005500:Follow-Up Studies; D006801:Humans; D016130:Immunophenotyping; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000627:therapeutic use; D007946:Leukemia, Mast-Cell / Q000188:drug therapy / Q000276:immunology* / Q000473:pathology; D008407:Mast Cells / Q000276:immunology / Q000473:pathology; D008415:Mastocytosis / Q000188:drug therapy / Q000276:immunology* / Q000473:pathology; D011994:Recombinant Proteins
D000911:Antibodies, Monoclonal; D000954:Antigens, Surface; D004273:DNA, Neoplasm; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins